Connecticut is currently home to 1247 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126
Recruiting
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Melanoma, Cutaneous Malignant
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738
Recruiting
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, West Haven, Connecticut
Conditions: Non-small Cell Lung Cancer
Register for Updates
FORWARD CAD IDE Study
NCT06662500
Recruiting
The FORWARD CAD IDE Study is a Prospective, Multicenter, Single-Arm, Investigational Device Exemption (IDE) Study conducted to assess the safety and effectiveness of the Shockwave Intravascular Lithotripsy (IVL) System with the Javelin Coronary IVL Catheter for the treatment of calcified, stenotic de novo coronary artery lesions prior to stenting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Coronary Arterial Disease (CAD)
Register for Updates
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
NCT06619587
Recruiting
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Solid Tumor
Register for Updates
Drinking, Acetate, and Stress
NCT06584448
Recruiting
The purpose of this study is to learn how drinking alcohol affects how people experience stress and how that is affected by the body's chemistry. Specifically, the investigators will be studying relationships of drinking and a stress hormone called cortisol. The investigators believe that results will lead us to find more effective ways to help people stop or reduce drinking when participants are drinking at harmful levels.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/25/2025
Locations: The Anlyan Center, 300 Cedar St., New Haven, Connecticut
Conditions: Alcohol Use Disorder, Alcohol Use, Unspecified, Heavy Drinker, Alcohol Use Disorder, Moderate, in Sustained Remission
Register for Updates
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06568939
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Yale New Haven Hospital /ID# 271584, New Haven, Connecticut
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616
Recruiting
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
07/25/2025
Locations: Yale University School Of Medicine, New Haven, Connecticut
Conditions: Preclinical Alzheimer's Disease
Register for Updates
Developing a Novel Human Laboratory Paradigm for AUD Medication Screening
NCT06489782
Recruiting
The intent of the study is to develop two versions of the 'ability to resist' drinking model designed to screen Alcohol Use Disorder (AUD) medications.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Alcohol Use Disorder
Register for Updates
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288
Recruiting
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat and empagliflozin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Bridgeport Hospital, Bridgeport, Connecticut
Conditions: Heart Failure
Register for Updates
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374
Recruiting
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Yale Cancer Center ( Site 0053), New Haven, Connecticut
Conditions: Triple-Negative Breast Cancer
Register for Updates
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
NCT06074068
Recruiting
The goal of this clinical trial is to test the efficacy of Fathers for Change (F4C) compared to standard Batterer Intervention for fathers with a history of Intimate Partner Violence. The main question\[s\] it aims to answer are: 1. Is F4C more efficacious than standard BIP in reducing family violence and child mental health impairment? 2. What are the trajectories of therapeutic change targets across interventions? 3. Does father's emotion regulation and reflective functioning mediate the rela... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Yale, New Haven, Connecticut
Conditions: Intimate Partner Violence, Child Maltreatment
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441
Recruiting
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Register for Updates